Online citations, reference lists, and bibliographies.
← Back to Search

Lipid Nanoparticles As Drug/gene Delivery Systems To The Retina.

A. Del Pozo-Rodríguez, D. Delgado, Alicia R. Gascón, M. Solinís
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This review highlights the application of lipid nanoparticles (Solid Lipid Nanoparticles, Nanostructured Lipid Carriers, or Lipid Drug Conjugates) as effective drug/gene delivery systems for retinal diseases. Most drug products for ocular disease treatment are marketed as eye drop formulations but, due to ocular barriers, the drug concentration in the retina hardly ever turns out to be effective. Up to this date, several delivery systems have been designed to deliver drugs to the retina. Drug delivery strategies may be classified into 3 groups: noninvasive techniques, implants, and colloidal carriers. The best known systems for drug delivery to the posterior eye are intravitreal implants; in fact, some of them are being clinically used. However, their long-term accumulation might impact the patient's vision. On the contrary, colloidal drug delivery systems (microparticles, liposomes, or nanoparticles) can be easily administered in a liquid form. Nanoparticular systems diffuse rapidly and are better internalized in ocular tissues than microparticles. In comparison with liposomes, nanoparticles have a higher loading capacity and are more stable in biological fluids and during storage. In addition, their capacity to adhere to the ocular surface and interact with the endothelium makes these drug delivery systems interesting as new therapeutic tools in ophthalmology. Within the group of nanoparticles, those composed of lipids (Solid Lipid Nanoparticles, Nanostructred Lipid Carriers, and Lipid Drug Conjugates) are more biocompatible, easy to produce at large scale, and they may be autoclaved or sterilized. The present review summarizes scientific results that evidence the potential application of lipid nanoparticles as drug delivery systems for the retina and also as nonviral vectors in gene therapy of retina disorders, although much more effort is still needed before these lipidic systems could be available in the market.
This paper references
10.1016/j.ijpharm.2011.12.052
Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice.
D. Delgado (2012)
10.1016/J.EJPB.2005.01.009
Cell culture models of the ocular barriers.
M. Hornof (2005)
In Vitro Model of Retinal Pigment Epithelium for Use in Drug Delivery Studies
E. Mannermaa (2010)
10.1615/CRITREVTHERDRUGCARRIERSYST.V26.I6.10
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.
A. Puri (2009)
10.1016/J.ADDR.2007.04.010
Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system.
P. Chattopadhyay (2007)
10.1167/iovs.10-6479
Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment.
Katherine E. Talcott (2011)
Lipid matrix-drug conjugates particle for controlled release of active ingredient
R. H. Müller (2004)
10.1016/j.jconrel.2009.05.033
New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis.
Laure Lajavardi (2009)
Transscleral delivery of bioactive protein to the choroid and retina.
J. Ambati (2000)
SOLID LIPID NANOPARTICLES: A REVIEW
P. Ekambaram (2012)
10.1021/mp8000233
Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA.
H. R. Kim (2008)
10.1089/hum.2011.115
Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis.
D. Delgado (2012)
10.1517/17425247.3.2.275
Ocular drug delivery
D. Ghate (2006)
10.1016/S0378-5173(00)00361-6
Studies on the cyclosporin A loaded stearic acid nanoparticles.
Q. Zhang (2000)
10.1089/108076801753162807
Review: practical issues in intravitreal drug delivery.
D. Maurice (2001)
10.1016/S1773-2247(10)50057-1
Cisplatin-loaded SLN produced by coacervation technique
M. Gallarate (2010)
10.1007/s11095-007-9234-3
Effect of Solid Lipid Nanoparticles Formulation Compositions on Their Size, Zeta Potential and Potential for In Vitro pHIS-HIV-Hugag Transfection
Rathapon Asasutjarit (2007)
10.1016/j.visres.2008.05.005
Barriers for retinal gene therapy: Separating fact from fiction
R. Kumar-Singh (2008)
10.1166/JBN.2011.1235
Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate.
Rishi Paliwal (2011)
10.2174/157016312799304552
Preparation and characterization of solid lipid nanoparticles-a review.
R. Parhi (2012)
10.1023/B:PHAM.0000048185.09483.e7
Stabilization of Proteins in Dry Powder Formulations Using Supercritical Fluid Technology
N. Jovanović (2004)
10.1016/J.DESAL.2006.03.455
A membrane contactor for the preparation of solid lipid nanoparticles
C. Charcosset (2006)
10.1016/j.jconrel.2010.07.079
Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations.
D. Doroud (2010)
10.5301/EJO.2010.6051
Drug Delivery to the Posterior Segment of the Eye
N. Fischer (2011)
10.1016/j.ijpharm.2010.10.008
Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution.
Jie Shen (2010)
10.1016/j.ijpharm.2009.10.020
Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration.
A. del Pozo-Rodríguez (2010)
10.1089/jop.2008.0031
Development of effective ocular preparations of antifungal agents.
I. P. Kaur (2008)
10.1016/j.ijpharm.2010.10.013
Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system.
Q. Luo (2011)
10.1167/iovs.03-1294
Delivery of gentamicin to the rabbit eye by drug-loaded hydrogel iontophoresis.
E. Eljarrat-Binstock (2004)
10.1056/NEJM199707103370203
Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group.
D. Musch (1997)
10.1016/j.ijpharm.2008.01.008
Solid lipid nanoparticles for pulmonary delivery of insulin.
J. Liu (2008)
10.1101/pdb.prot068122
Formation of solid lipid nanoparticle (SLN)-gene vector complexes for transfection of mammalian cells in vitro.
Carsten Rudolph (2012)
10.1016/J.EJPB.2007.07.006
Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation.
R. Mueller (2008)
10.1016/j.colsurfb.2012.01.001
Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration.
Vinay Kumar Venishetty (2012)
10.1038/mt.2010.147
Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver.
Weikang Tao (2010)
10.1016/S0169-409X(02)00118-7
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations.
R. Mueller (2002)
10.1167/IOVS.02-0791
Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.
U. Kompella (2003)
10.1089/jop.2011.0060
Intravitreal bevacizumab for retinopathy of prematurity.
B. Harder (2011)
10.1016/S0939-6411(01)00157-6
Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits.
M. Sznitowska (2001)
10.3109/02652048.2011.590612
Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies
Shamsunder S Dodiya (2011)
Medication vehicles made of solid lipid particles (solid lipid nanospheres sln)
룩크스 스테판 (1992)
Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats
S. Camelo (2007)
10.1088/0957-4484/21/2/025101
Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement.
Jie Shen (2010)
10.2174/1389557053175335
Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs.
J. M. Irache (2005)
10.1021/nn203745n
In vivo sustained release of siRNA from solid lipid nanoparticles.
Tatsiana Lobovkina (2011)
10.3109/03639045.2010.522193
Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo
Zhidong Liu (2011)
10.1016/J.ADDR.2006.07.027
Challenges and obstacles of ocular pharmacokinetics and drug delivery.
A. Urtti (2006)
Solid lipid nanoparticles (SLN) : an alternative colloidal carrier system for controlled drug delivery
R. Mueller (1995)
10.1016/j.ejpb.2008.09.003
Lipid nanoparticles for parenteral delivery of actives.
Medha D. Joshi (2009)
10.1023/A:1016278302046
Structures of Nanoparticles Prepared from Oil-in-Water Emulsions
B. Sjoestroem (2004)
10.1073/pnas.1018987108
Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration
K. Zhang (2011)
10.1155/2011/747648
The Use of Intravitreal Ranibizumab for Choroidal Neovascularization Associated with Vogt-Koyanagi-Harada Syndrome
A. Kolomeyer (2011)
10.1517/17425247.4.4.371
Novel approaches to retinal drug delivery
Kumar G. Janoria (2007)
10.1016/j.jconrel.2008.09.004
A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors.
A. Del Pozo-Rodríguez (2009)
10.1517/17425247.2012.673278
Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery
L. Battaglia (2012)
10.1016/j.preteyeres.2004.02.003
Drug delivery systems for vitreoretinal diseases
T. Yasukawa (2004)
10.1080/02713680701528674
Methotrexate Delivery to the Eye Using Transscleral Hydrogel Iontophoresis
E. Eljarrat-Binstock (2007)
10.1002/jps.22784
Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels.
E. Gonzalez-Mira (2012)
10.1016/B978-0-12-391860-4.00015-X
Chitosan-coated solid lipid nanoparticles for insulin delivery.
P. Fonte (2012)
10.1016/j.ejpb.2011.06.005
Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway.
D. Delgado (2011)
10.1016/j.colsurfb.2011.11.051
Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin.
D. M. Ridolfi (2012)
10.1016/j.ijpharm.2008.04.023
Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells.
A. Del Pozo-Rodríguez (2008)
10.1016/0168-3659(94)90047-7
Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization
C. Schwarz (1994)
Retinal delivery of sodium fluorescein, budesonide & celecoxib following subconjunctival injection
N.P.S. Cheruvu (2003)
10.1002/jps.21434
Production of solid lipid submicron particles for protein delivery using a novel supercritical gas-assisted melting atomization process.
S. Salmaso (2009)
10.2174/1389450053765914
Colloidal carriers for ophthalmic drug delivery.
R. Mainardes (2005)
10.1016/S1350-9462(01)00018-0
Transscleral drug delivery to the retina and choroid
J. Ambati (2002)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.3109/03639045.2012.665460
Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir
A. Seyfoddin (2013)
10.1016/j.preteyeres.2010.08.002
Applications of nanoparticles in ophthalmology
Y. Diebold (2010)
10.1016/J.SURVOPHTHAL.2006.02.006
A review of anterior segment dysgeneses.
F. Idrees (2006)
10.1016/J.IJPHARM.2007.03.022
Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability.
Veerawat Teeranachaideekul (2007)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1155/2011/132435
Peptide-Loaded Solid Lipid Nanoparticles Prepared through Coacervation Technique
Marina Gallarate (2011)
10.3310/hta16060
Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK.
B. Reeves (2012)
10.3109/02652048.2010.539304
A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide
R. Li (2011)
10.1016/J.ADDR.2005.09.006
Micro- and nanoparticulates.
A. Moshfeghi (2005)
10.1016/J.YMTHE.2004.09.022
Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain.
N. Provost (2005)
10.1201/9780203912072-18
Microparticles and Nanoparticles in Ocular Drug Delivery
Murali K. Kothuri (2003)
Hereditary X-linked juvenile retinoschisis: a review of the role of Müller cells.
C. Mooy (2002)
10.1016/J.ADDR.2007.04.007
Solid lipid nanoparticles as a drug delivery system for peptides and proteins.
A. Almeida (2007)
10.3109/02652048.2010.513456
Solid lipid nanoparticles for transdermal delivery of diclofenac sodium: preparation, characterization and in vitro studies
D. Liu (2010)
Nanostructured Lipid Carriers : A Novel Generation of Solid Lipid Drug Carriers
M. Radtke (2005)
10.1016/S0169-409X(01)00193-4
Transscleral drug delivery for posterior segment disease.
D. Geroski (2001)
10.1016/S0939-6411(02)00130-3
Solvent injection as a new approach for manufacturing lipid nanoparticles--evaluation of the method and process parameters.
M. Schubert (2003)
10.1002/eji.200425022
Intraocular injection of tamoxifen‐loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis
Y. de Kozak (2004)
10.3109/02652040902846883
Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery
E. Başaran (2010)
10.1080/02652040701532981
Solid lipid nanoparticles formed by solvent-in-water emulsion–diffusion technique: Development and influence on insulin stability
L. Battaglia (2007)
10.1016/j.colsurfb.2011.06.025
Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye.
J. Araújo (2011)
10.1167/IOVS.03-0600
Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model.
Y. Saishin (2003)
10.1080/10837450600561182
Influence of the Formulation for Solid Lipid Nanoparticles Prepared with a Membrane Contactor
Assma Ahmed El-Harati (2006)
10.1016/J.JCONREL.2004.02.024
Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption.
C. Olbrich (2004)
10.3310/hta16430
The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
M. Cherry (2012)
Method for producing solid lipid microspheres having a narrow size distribution
M. R. Gasco (1993)
10.1016/j.ejpb.2008.09.015
Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy.
A. Del Pozo-Rodríguez (2009)
Drug release and release mechanism of prednisolone loaded Solid Lipid Nanoparticles
A. Z. Mühlen (1998)
10.1007/s11095-008-9694-0
Recent Perspectives in Ocular Drug Delivery
Ripal Gaudana (2008)
10.1016/J.EJMECH.2005.07.015
Synthesis of acridine-nuclear localization signal (NLS) conjugates and evaluation of their impact on lipoplex and polyplex-based transfection.
C. Boulanger (2005)
10.3109/10717544.2011.621989
The role of protamine amount in the transfection performance of cationic SLN designed as a gene nanocarrier
E. Vighi (2012)
10.1517/17425247.5.9.1039
Iluvien™: a new sustained delivery technology for posterior eye disease
F. Kane (2008)
10.2174/138161209788923886
Nanocarriers in ocular drug delivery: an update review.
Sheetu Wadhwa (2009)
10.1167/IOVS.04-1051
Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity.
L. Pitkänen (2005)
10.1016/j.ijpharm.2010.08.044
Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells.
A. Siddiqui (2010)
10.1016/j.ijpharm.2007.12.007
Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct.
A. Attama (2008)
10.1016/J.IJPHARM.2006.12.043
Formulation and characterization of curcuminoids loaded solid lipid nanoparticles.
W. Tiyaboonchai (2007)
10.1080/02713680903017500
Sustained Release and Permeation of Timolol from Surface-Modified Solid Lipid Nanoparticles through Bioengineered Human Cornea
A. Attama (2009)
10.1016/j.ijpharm.2008.07.028
Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity.
E. Gokce (2008)
10.1016/S0378-5173(02)00080-7
Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin.
R. Cavalli (2002)
10.1016/J.OPHTHA.2006.02.021
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
G. Jaffe (2006)
10.1159/000093796
Intravitreal Triamcinolone Acetonide: A Change in a Paradigm
J. Jonas (2006)
10.1007/s11095-009-0042-9
New Techniques for Drug Delivery to the Posterior Eye Segment
E. Eljarrat-Binstock (2009)
10.1167/IOVS.02-1068
Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles.
Jean-Louis Bourges (2003)
10.1021/BC0601166
Employment of cationic solid-lipid nanoparticles as RNA carriers.
G. Montana (2007)
10.2174/187221111797200597
New methods for lipid nanoparticles preparation.
F. Corrias (2011)
10.1007/s11095-005-7547-7
Blood Compatibility of Cetyl Alcohol/Polysorbate-Based Nanoparticles
J. Koziara (2005)
10.1016/J.JTBI.2005.12.015
The probable structure of the protamine-DNA complex.
K. Biegeleisen (2006)
Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives
Melike Üner (2007)
10.1126/scitranslmed.3002865
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
J. Bennett (2012)
10.1080/1061186021000001832
Lipid-Drug-Conjugate (LDC) Nanoparticles as Novel Carrier System for the Hydrophilic Antitrypanosomal Drug Diminazenediaceturate
C. Olbrich (2002)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.1016/j.biomaterials.2009.03.016
Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent.
A. Agarwal (2009)
10.3109/02713681003760168
Feasibility of Lipid Nanoparticles for Ocular Delivery of Anti-Inflammatory Drugs
E. Souto (2010)
Current and future ophthalmic drug delivery systems
E. Amo (2008)
10.1016/J.IJPHARM.2007.03.015
Solid lipid nanoparticles: formulation factors affecting cell transfection capacity.
A. Del Pozo-Rodríguez (2007)
10.1016/J.EJPB.2004.12.007
Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation.
K. Hosoya (2005)
10.1016/S0140-6736(09)61836-5
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
A. Maguire (2009)
Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles.
L. Hu (2010)
10.2165/11530970-000000000-00000
Biodegradable Intraocular Therapies for Retinal Disorders
N. Kuno (2010)
10.1016/j.ijpharm.2010.03.034
Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications.
J. Araújo (2010)
10.1016/j.ophtha.2012.02.003
Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
P. Kaiser (2012)
10.1016/J.EJPB.2005.11.003
Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation.
Thami Sebti (2006)
10.1089/jop.2007.0097
Methylprednisolone delivery to the back of the eye using hydrogel iontophoresis.
E. Eljarrat-Binstock (2008)
10.1016/J.IJPHARM.2005.09.023
Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.
Ahmed S. Guinedi (2005)
Solid lipid nanoparticles for parenteral drug
S. A. Wissing (2004)
10.1167/IOVS.07-0066
Coated microneedles for drug delivery to the eye.
J. Jiang (2007)
10.1167/IOVS.03-1294
Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Müller cells.
L. Kusner (2004)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.1016/j.exer.2008.04.009
Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration.
E. Souied (2008)
10.1016/S0014-4835(03)00211-2
Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems.
Sang-Bumm Lee (2004)
Drug delivery for posterior segment eye disease.
D. Geroski (2000)
10.1016/j.ijpharm.2010.01.030
pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles.
E. Vighi (2010)
10.1167/iovs.09-4373
Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes.
R. Zhang (2010)
10.1517/17425247.1.1.99
Periocular routes for retinal drug delivery
Swita Raghava (2004)
10.2174/157016311796799062
20 Years of Lipid Nanoparticles (SLN & NLC): Present State of Development & Industrial Applications
R. Mueller (2011)
10.1016/J.EJPB.2005.09.003
Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands.
N. Pedersen (2006)
10.1089/JOP.2011.0184
Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion.
S. Bakri (2012)
10.1016/S0014-4835(03)00215-X
Iontophoresis-gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe.
J. Fruchtpery (2004)
10.1016/J.EJPHAR.2005.02.019
Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model.
S. Ayalasomayajula (2005)
10.2174/187221108784534081
Recent advances and patents on solid lipid nanoparticles.
K. Sawant (2008)
10.1097/ICU.0b013e3281108000
Drug delivery methods for posterior segment disease
Jason Hsu (2007)
10.1016/J.EJPB.2007.07.011
Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells.
S. Choi (2008)
10.3109/03639040903241817
Electrospray technique for solid lipid-based particle production
M. Trotta (2010)
10.1080/10611860701324698
Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery
M. Bondì (2007)
10.1248/CPB.56.1645
Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying.
X. Zhang (2008)
10.1167/IOVS.01-1156
Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres.
K. Carrasquillo (2003)
tran conjugated dendritic nanoconstructs as potential vectors for anti - cancer agent
A. Agarwal (2009)
Solid lipid nanoparticles formed by solventin - water emulsiontechnique : Development and influences on insulin stability
N. Jovanovic (2007)
10.1016/J.EJPS.2005.06.001
Adaptation and optimization of the emulsification-diffusion technique to prepare lipidic nanospheres.
D. Quintanar-Guerrero (2005)
10.1016/j.ejpb.2008.05.008
Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).
Jia-You Fang (2008)
10.3109/10717544.2010.483257
Solid lipid nanoparticles for ocular drug delivery
A. Seyfoddin (2010)
10.1016/0039-6257(84)90168-1
Ophthalmic drug delivery systems
J. Shell (1984)
10.1007/978-1-59745-375-2_21
Barriers in Ocular Drug Delivery
Sriram Gunda (2008)
Lipid nanoparticles for gene therapy
A. R. Gascón (2011)
10.1002/jps.22813
Novel surface-modified nanostructured lipid carriers with partially deacetylated water-soluble chitosan for efficient ocular delivery.
Baocheng Tian (2012)
Treatment of cytomegalovirus retinitis in AIDS patients with intravitreal ganciclovir.
S. Ausayakhun (2005)
10.1016/J.JCONREL.2005.07.023
Preparation of solid lipid nanoparticles using a membrane contactor.
C. Charcosset (2005)
10.1517/17425247.2012.666967
Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals
C. Puglia (2012)
10.1016/j.drudis.2007.10.021
Nanotechnology in ocular drug delivery.
S. Sahoo (2008)
10.1517/14712598.3.1.45
Drug delivery to the retina: challenges and opportunities
Sridhar Duvvuri (2003)
10.1211/jpp.59.5.0002
Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops
T. Loftsson (2007)
10.1016/S0378-5173(02)00180-1
Nanostructured lipid matrices for improved microencapsulation of drugs.
R. Mueller (2002)
10.1056/NEJMoa0802268
Effect of gene therapy on visual function in Leber's congenital amaurosis.
J. Bainbridge (2008)



This paper is referenced by
10.1016/j.ijpharm.2019.118987
Novel Liposome Aggregate Platform (LAP) system for sustained retention of drugs in the posterior ocular segment following intravitreal injection.
S. Blazaki (2019)
10.1007/978-3-030-45923-9_25
Role of Nanoparticles in the Management of Metabolic Disorders
Z. Iqbal (2021)
10.12816/0001621
Bionanotechnology : The Novel Nanoparticles Based Approach for Disease Therapy
A. Mahasneh (2013)
10.1016/j.ejpb.2016.10.013
Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye – Part II ‐ Ocular drug‐loaded lipid nanoparticles
E. Sánchez-López (2017)
10.1089/jop.2017.0052
Relevance of Lipid-Based Products in the Management of Dry Eye Disease
Jean-Sébastien Garrigue (2017)
10.1016/j.ijpharm.2017.03.003
The diffusion dynamics of PEGylated liposomes in the intact vitreous of the ex vivo porcine eye: A fluorescence correlation spectroscopy and biodistribution study.
Anne Z. Eriksen (2017)
10.2174/1381612825666190903155321
Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery.
Kuldeep Rajpoot (2019)
10.1021/nl502275s
Nanoparticle-Assisted Targeted Delivery of Eye-Specific Genes to Eyes Significantly Improves the Vision of Blind Mice In Vivo
Ammaji Rajala (2014)
10.1016/j.jconrel.2015.09.033
Solid lipid nanoparticle-based vectors intended for the treatment of X-linked juvenile retinoschisis by gene therapy: In vivo approaches in Rs1h-deficient mouse model.
P. S. Apaolaza (2015)
10.1089/JOP.2017.0052
Relevance of Lipid-Based Products in the Management of Dry Eye Disease.
GarrigueJean-Sébastien (2017)
10.3390/jfb6020379
Lipid Nanoparticles for Ocular Gene Delivery
Yuhong Wang (2015)
10.1016/j.ijpharm.2014.04.061
Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles.
A. Leonardi (2014)
10.1016/j.ijpharm.2017.09.017
Designing lipid nanoparticles for topical ocular drug delivery.
J. Álvarez-Trabado (2017)
10.4155/tde.15.73
Ophthalmic applications of lipid-based drug nanocarriers: an update of research and patenting activity.
R. Pignatello (2015)
10.1088/2053-1591/AA67B4
Temperature-controlled continuous production of all-trans retinoic acid-loaded solid lipid nanoparticles using static mixers
Wenyao Shao (2017)
10.1089/JOP.2011.0184
Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion.
S. Bakri (2012)
10.1016/j.actbio.2015.06.012
A sustained intravitreal drug delivery system with remote real time monitoring capability.
Huiyuan Hou (2015)
10.1016/j.visres.2014.07.013
Promising and delivering gene therapies for vision loss
L. Carvalho (2015)
10.1002/9781118856017.CH13
Nanomedicine for the Brain and the Eye: Disease Management in Poorly Accessible Compartments of the Body
A. G. Cattaneo (2014)
10.1208/s12249-014-0168-x
Characterization and Evaluation of 5-Fluorouracil-Loaded Solid Lipid Nanoparticles Prepared via a Temperature-Modulated Solidification Technique
M. Patel (2014)
10.5539/JFR.V3N4P3
Novel Neuroprotective Formulations Based on St. John’s Wort Extract
M. Vazzana (2014)
10.4155/ppa.13.79
Pharmaceutical and biomedical applications of lipid-based nanocarriers.
C. Carbone (2014)
10.1016/j.ijpharm.2017.07.039
Nano lipid-drug conjugate: An integrated review.
Piya Adhikari (2017)
10.22037/IJPR.2016.1830
Ocular Dorzolamide Nanoliposomes for Prolonged IOP Reduction: in-vitroand in-vivo Evaluation in Rabbits
M. Kouchak (2016)
10.1016/j.ejpb.2014.12.022
Treatment of ocular disorders by gene therapy.
M. A. Solinís (2015)
10.1016/j.nano.2015.09.004
Nanostructured lipid carriers: Promising drug delivery systems for future clinics.
A. Beloqui (2016)
Dosage forms in therapy of posterior segments of the eye
Lucie Pospěchová (2016)
The Future of Vitrectomy
Jean-Pierre Hubschman (2014)
10.1016/j.apsb.2016.09.001
Nanotechnology-based strategies for treatment of ocular disease
Yuhua Weng (2017)
10.1155/2014/161794
Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives
J. Torrecilla (2014)
10.1590/S1415-47572014000200015
A snapshot of gene therapy in Latin America
R. Linden (2014)
10.1136/bjophthalmol-2013-304028
Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine
N. Kim (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar